Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410670 · ClinicalTrials.gov registry record
Chordoma Family Study
A clinical trial of Chordoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 55
- Enrollment target
- 1
- Study location
NCT00410670: Completed study of Chordoma, sponsored by National Cancer Institute (NCI).
NCT00410670 is a study of Chordoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 55 participants, below the 83-participant average among 15 other Chordoma trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00410670, a study of Chordoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study, conducted by the National Cancer Institute and the Massachusetts General Hospital, will investigate genetic factors that contribute to the development of chordoma in people from some families. Chordoma is a very rare, potentially fatal, slow-growing bone tumor derived from remnants of embryonic material. This study will determine the feasibility of conducting a larger study aimed at identifying new families with multiple members affected by chordoma to study the genetic basis of the disease. English-speaking persons diagnosed with chordoma when they were 18 years of age or younger and who were treated at the Massachusetts General Hospital Department of Radiation Oncology between 1988 and the end of the study period may be eligible for this protocol. The age range of these patients is currently from about 5 months to 33 years. Patients (or parents of minor patients) will be mailed a packet with instructions for completing the following procedures at home: * Provide permission for researchers to obtain medical records relating to the patient's chordoma and any other serious medical conditions he or she has had, and to obtain a piece of the patient's stored tumor tissue. * Complete a questionnaire about the patient's close blood relatives, including parents, brothers, sisters, and any more distant relatives who have had chordoma or a cancer or tumor which started in the brain or spine. The questionnaire will also include demographic information, such as education, marital status, ethnicity, religion, and household income. * Collect two samples of cheek cells (only from patients 6 years and older). Patients' packets include instructions and materials for collecting the cells. Parents of children 6 to 9 years old will collect cells from the child's mouth using a sterile soft-bristled brush contained in a tube. They will brush the inside of the child's cheek with the brush for about 30 seconds and then place the brush back in the tube. They will repea
Conditions Studied
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2003-08-01 |
| Est. Completion | 2017-12-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00410670
The ClinicalTrials.gov registry entry for NCT00410670 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 15 other Chordoma trials with a reported enrollment target (34% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chordoma appearing as the primary indexed condition, and to 0 interventions.
NCT00410670 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00410670 about?
NCT00410670 is a clinical study titled "Chordoma Family Study". This pilot study, conducted by the National Cancer Institute and the Massachusetts General Hospital, will investigate genetic factors that contribute to the development of chordoma in people from some families. Chordoma is a very rare, potentially fatal, slow-growing bone tumor derived from remnants...
What is the current status of trial NCT00410670?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2003-08-01. Estimated completion is 2017-12-29.
What conditions does trial NCT00410670 study?
This clinical trial studies the following conditions: Chordoma.
Who is sponsoring clinical trial NCT00410670?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00410670 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chordoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Children and Adults With Chordoma
RECRUITING
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
RECRUITING
-
Pembrolizumab and Pemetrexed for Progressive Chordoma
RECRUITING · Phase 2
-
Long-Term Longitudinal QoL in Patients Undergoing EEA
RECRUITING
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.